Top-News
Dienstag,
15.08.2017 12:00
von
PR Newswire
| Aufrufe: 81
China Pharma Holdings, Inc. Reports Second Quarter 2017 Financial Results
Die chinesische Flagge.
pixabay.com
PR Newswire
HAIKOU CITY, China, Aug. 15, 2017
HAIKOU CITY, China, Aug. 15, 2017 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE MKT: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the quarter ended June 30, 2017.
Second Quarter Highlights
- Revenue decreased 17.7% to $2.9 million in second quarter 2017 from $3.5 million in the same period of 2016;
- Gross profit margin was 22.2% in second quarter 2017, compared to 13.6% in the same period of 2016.
- Loss from operations was $2.1 million in second quarter 2017 compared to $2.2 million in the same period of 2016, a decrease of $0.1 million in loss;
- Net loss was $2.3 million in second quarter 2017 compared to $2.5 million in the same period of 2016. Loss per common share was $(0.05) per basic and diluted share in second quarter 2017 compared with $(0.06) per basic and diluted share in the same period of 2016.
"We experienced a slight revenue decrease in the second quarter of 2017 compared to the same period last year, which was primarily due to the current status of Chinese health care reform. Recent reforms require health care institutions to strictly control 'the proportion of drug sales to total revenue', in an effort to prevent hospitals from subsidizing medical services with inflated prescription drug prices. This background led to a significant decrease of drug purchases from health care institutions and impacted our drug sales in this period," said Ms. Zhilin Li, China Pharma's Chairman and CEO. Ms. Li continued, "Nevertheless, increasing sales remains our top priority. Management will continue to vigorously promote sales by actively participating in the recent provincial market openings to receive new drug tender offers and by further exploring the basic medical market. The ongoing generic drug consistency evaluations and reform of China's drug production registration and review policies will have a major impact on the future development of our industry and may change its business patterns. We will continue to actively adapt to state policy guidance and further evaluate market conditions for our current existing products, pipeline products, and competition in the market in order to optimize our development strategy."
Second Quarter Results
Revenue decreased by 17.7% to $2.9 million for the three months ended June 30, 2017, as compared to $3.5 million for the three months ended June 30, 2016. This decrease was mainly due to the impact from the ongoing Chinese health care reform.
Gross profit for the three months ended June 30, 2017 was $0.6 million, compared to $0.5 million in the same period last year. Our gross profit margin in the three months ended June 30, 2017 was 22.2% compared to 13.6% in the same period last year. This increase was primarily due to more sales of higher margin products in this period compared to the sales performance in the same period last year.
Our selling expenses for the three months ended June 30, 2017 were $0.8 million, a decrease of $0.1 million, compared to $0.9 million for the three months ended June 30, 2016. Selling expenses accounted for 27.5% of the total revenue in the three months ended June 30, 2017 compared to 24.2% in the same period last year. Because of adjustments in our sales practices resulting from health-care reform policies, despite the overall decrease in sales, we may require additional personnel and expenses to support our sales and the collection of accounts receivable.
Our general and administrative expenses for the three months ended June 30, 2017 were $0.6 million, which represented a decrease of $0.2 million compared to $0.8 million in the same period last year. General and administrative expenses accounted for 21% and 22% of our total revenues in three months ended June 30, 2017 and 2016, respectively.
Our bad debt expenses for the three months ended June 30, 2017 was $0.4 million, compared to $0.5 million in the same period last year.
During the three months ended June 30, 2017 and 2016 the Company recognized an impairment related to "Advances for purchases of intangible assets" in the amount of $1.0 million and $0.8 million, respectively. The Company reviewed the contracts relating to advances made for purchases of intangible assets with independent laboratories and determined that the Company's advances to independent laboratories for several formulas were impaired.
Net loss for the three months ended June 30, 2017 was $2.3 million, compared to net loss of $2.5 million for the three months ended June 30, 2016.
Six Months Results
For the six months ended June 30, 2017, our sales revenue was $6.2 million, which represented a decrease of $1.0 million, or 13.7%, from the $7.2 million in the corresponding period of 2016.
Gross profit for the six months ended June 30, 2017 was $1.4 million, compared to $1.1 million in the same period of 2016. Gross profit margin for the six months ended June 30, 2017 and 2016 were 22.0% and 15.6%, respectively. The increase in gross profit margin was mainly due to more higher-margin products sold in this period.
Our operating loss for the six months ended June 30, 2017 was approximately $2.9 million, compared to $3.5 million for the same period of 2016, which represented an improvement of $0.6 million. This was mainly due to the increase in gross profit margin and decrease in bad debt expense in the first half of 2017 compared to the same period last year.
Net loss was $3.3 million, or $0.07 per basic and diluted share for the six months ended June 30, 2017, compared to $4.0 million, or $0.09 per basic and diluted share, for the same period a year ago.
Financial Condition
As of June 30, 2017, the Company had cash and cash equivalents of $1.7 million compared to $2.7 million as of December 31, 2016. Working capital decreased to $6.7 million as of June 30, 2017 from $7.1 million as of December 31, 2016; and the current ratio was 1.6 and 1.7 times at June 30, 2017 and December 31, 2016, respectively.
Our net accounts receivable balance decreased to $3.2 million as of June 30, 2017 from $4.0 million as of December 31, 2016.
Conference Call
The Company will hold a conference call at 8:30 am E.T. on August 15, 2017 to discuss the results of second quarter 2017. Listeners may access the call by dialing 1-866-519-4004 or 65-671-350-90 for international callers, Conference ID # 66755768. A replay of the call will be accessible through August 23, 2017 by dialing 1-855-452-5696 or 61-281-990-299 for international callers, Conference ID # 66755768.
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high-margin business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit www.chinapharmaholdings.com. The Company routinely posts important information on its website.
Safe Harbor Statement
Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as the achievability of financial guidance, success of new product development, unanticipated changes in product demand, increased competition, downturns in the Chinese economy, uncompetitive levels of research and development, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations except as required by applicable law or regulation.
Contact:
China Pharma Holdings, Inc.
Ms. Diana Na Huang
Phone: +86-898-6681-1730 (China)
Email: hps@chinapharmaholdings.com
- FINANCIAL TABLES FOLLOW -
| CHINA PHARMA HOLDINGS, INC. | ||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||
| | ||||
| | | | | |
| | | June 30, | | December 31, |
| | | 2017 | | 2016 |
| ASSETS | | (Unaudited) | | (Audited) |
| Current Assets: | | | | |
| Cash and cash equivalents | | $ 1,745,566 | | $ 2,665,802 |
| Restricted cash | | 2,568,895 | | 1,088,879 |
| Bankers acceptance notes | | 16,692 | | - |
| Trade accounts receivable, less allowance for doubtful | | | | |
| accounts of $16,805,221 and $15,664,496, respectively | | 3,152,815 | | 3,999,809 |
| Other receivables, less allowance for doubtful | | | | |
| accounts of $60,627 and $71,548, respectively | | 217,527 | | 224,373 |
| Advances to suppliers | | 2,063,172 | | 2,003,792 |
| Inventory | | 7,258,973 | | 7,310,939 |
| Prepaid expenses | | 185,543 | | 226,357 |
| Total Current Assets | | 17,209,183 | | 17,519,951 |
| | | | | |
| Advances for purchases of intangible assets | | 35,381,708 | | 35,498,059 |
| Property, plant and equipment, net | | 24,080,326 | | 24,967,448 |
| Intangible assets, net | | 453,376 | | 534,682 |
| TOTAL ASSETS | | $ 77,124,593 | | $ 78,520,140 |
| | | | | |
| LIABILITIES AND STOCKHOLDERS' EQUITY | | | | |
| Current Liabilities: | | | | |
| Trade accounts payable | | $ 2,149,331 | | $ 3,060,374 |
| Accrued expenses | | 129,516 | | 139,830 |
| Other payables | | 2,294,358 | | 2,502,694 |
| Advances from customers | | 655,350 | | 811,232 |
| Other payables - related parties | | 1,354,567 | | 1,354,567 |
| Current portion of construction loan facility | | 1,328,043 Werbung Mehr Nachrichten zur China Pharma Holdings Inc Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE (Mit der Bestellung akzeptierst du die Datenschutzhinweise) -1  Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink. Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte. Andere Nutzer interessierten sich auch für folgende News | ||
